PREISIG, DANIEL,BRAVO GONZALEZ, ROBERTO CARLOS,OLIVEIRA VARUM, FELIPE JOSE
申请号：
ARP170101621
公开号：
AR108729A1
申请日:
2017.06.14
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
The utility model relates to a multi unit medicinal material composed of a core, wherein the core is composed of a plurality of units, each unit includes an active pharmaceutical principle, each unit includes an adhesive material, and the multi unit medicinal material also includes, A coating of the core In addition, this multi unit drug is used in the treatment of inflammation, especially in the intestinal tract. Claim 2: the multi unit pharmaceutical form described in claim 1,The coating (b) with the characteristic of core includes an additional coating (B2),Additional cladding (B2) between core (A) and outer cladding (B1),The additional coating (B2) comprises a polymer soluble in intestinal or gastric juice, selected from the group, consisting of at least partially neutralized polycarbonate polymer and a non-ionic polymer, each combined with at least one polymer. Additive selected from inducer and / or base and mixture. 44. Claim 4: the multi unit pharmaceutical form referred to in any of the above claims is characterized by the presence of at least one adhesive (A2) containing Shiite or alejanato,preferentemente chitos n Reivindicaci n 12 La forma farmac utica unitaria m ltiple de acuerdo con cualquiera de las reivindicaciones 1 a 11 caracterizada porque el principio activo para uso farmac utico (a1) se selecciona de metronidazol vancomicina cido 5-amino-salic lico budesonida y antiUna forma farmacéutica de unidades múltiples que comprende un núcleo, donde el núcleo comprende una pluralidad de unidades individuales, donde cada unidad comprende un principio farmacéuticamente activo y cada unidad está cubierta con un material muco-adhesivo, y donde la forma farmacéutica de unidades múltiples comprende, además, una capa de recubrimiento del núcleo. Además, uso de dicha forma farmacéutica de unidades múltiples en el tratamiento de trastornos inflamatorios, en especial para el tracto gastrointestinal. Reivindicación 2: La forma farmacéutica de unidades múltiples de a
